Lorazepam%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252528representative%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520benzodiazepine%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252529

# Lorazepam ## Overview Lorazepam is a benzodiazepine with anxiolytic, sedative, hypnotic, amnestic, anticonvulsant, and muscle relaxant properties. ## Primary Indications * Anxiety disorders * Insomnia (short-term treatment) * Status epilepticus * Sedation (pre-procedural or for mechanically ventilated patients) * Management of acute alcohol withdrawal symptoms ## Adult Dosing * **Anxiety:** 0.5 mg to 2 mg orally every 6 to 8 hours as needed. Maximum daily dose typically not to exceed 10 mg. * **Insomnia:** 2 mg to 4 mg orally at bedtime. * **Status Epilepticus:** 4 mg intravenously (IV) or intramuscularly (IM). A second dose of 4 mg may be administered after 5 to 10 minutes if seizures persist. * **Pre-procedural Sedation:** 1 mg to 4 mg IV, IM, or orally 2 hours prior to procedure. * **Sedation (Mechanically Ventilated Patients):** 0.02 mg/kg to 0.04 mg/kg IV every 2 to 6 hours as needed. Target RASS score of -4 to -5. * **Acute Alcohol Withdrawal:** 1 mg to 4 mg orally or IV/IM every 4 to 6 hours as needed. Dosing should be guided by symptom severity and patient response. *Note: Specific dosing for certain indications, particularly ICU sedation and alcohol withdrawal, may vary based on institutional protocols and patient-specific factors.* ## Pediatric Dosing * **Status Epilepticus:** 0.05 mg/kg IV/IM, maximum dose 4 mg. A second dose may be given after 5-10 minutes if seizures persist. * **Sedation (Pre-procedural):** Limited data. Doses of 0.02 mg/kg to 0.05 mg/kg orally or IV have been used, typically not exceeding adult doses. * **Pediatric Anesthesia/ICU Sedation:** Dosing is highly variable and requires careful titration based on clinical response and age. Consult specialized pediatric resources or protocols. ## Dose Adjustments * **Hepatic Impairment:** Use with caution; may require dose reduction. * **Renal Impairment:** No specific dose adjustment is typically recommended, but caution is advised, especially in severe impairment. ## Contraindications * Known hypersensitivity to lorazepam, other benzodiazepines, or any component of the formulation. * Acute narrow-angle glaucoma. * Severe respiratory insufficiency. * Severe hepatic insufficiency. * Myasthenia gravis (relative contraindication). * Sleep apnea. ## Adverse Effects Common: Drowsiness, dizziness, weakness, ataxia, confusion. Serious: Respiratory depression, paradoxical reactions (agitation, hallucinations), anterograde amnesia, dependence and withdrawal symptoms upon abrupt discontinuation, severe hypotension (especially with rapid IV administration). ## Key Drug Interactions * **CNS Depressants (opioids, alcohol, other sedatives/hypnotics, antihistamines):** Additive CNS depression, increasing the risk of sedation, respiratory depression, and death. Use with extreme caution and consider dose reduction of one or both agents. * **Theophylline/Aminophylline:** May antagonize the sedative effects of lorazepam. * **Valproic acid:** May decrease lorazepam clearance and increase serum concentrations. ## Monitoring * Respiratory rate, depth, and oxygen saturation. * Level of consciousness and sedation (e.g., using RASS score in ICU). * Blood pressure and heart rate. * Signs of withdrawal upon discontinuation. * Effectiveness for the intended indication. ## Clinical Pearls * Lorazepam has a longer half-life than some other parenteral benzodiazepines, which can be advantageous for sustained sedation but may also lead to prolonged recovery. * Intravenous lorazepam should be administered slowly to minimize adverse effects such as hypotension and respiratory depression. Do not exceed 2 mg/min. * For IM administration, the solution may be painful. * Avoid abrupt discontinuation due to risk of withdrawal symptoms, which can be severe. Taper dose gradually. * Use with caution in the elderly, as they are more susceptible to adverse effects like confusion and falls. *** **Disclaimer:** This information is intended for healthcare professionals. Always consult the official prescribing information and relevant clinical guidelines for complete and up-to-date information before making any treatment decisions.